2nd Circ. Quashes Savient Investor's Class Action
The Second Circuit on Friday backed the dismissal of a putative securities fraud class action accusing Savient Pharmaceuticals Inc. of misleading investors by holding back reports of adverse reactions to its...To view the full article, register now.
Already a subscriber? Click here to view full article